Scarlett is hunting sharks perhaps in the North Pole area and Anna is home worrying about Brexit. Others are just taking a nice nap!
That I know ! What I am asking is that explain why you think the JNJ LOCK is undesirable if the patent expiry is extended to 2032 (from originally 2025), if it is contracted already that JNJ is in full charge of all IMET development work and that it is also responsible for manufacturing and distribution of IMET. Once IMET is licensed and is marketed, Geron gets its percentage. Also, because JNJ will be marketing it using all its resources that are far far more formidable than the bozos at Geron can have! Then, why is it undesirable that for doing all that JNJ gets its share whileGeron doing nothing gets its industry-high percentage?
We all know it is in Ph 3!! What I meant is that the appointment of DMC is not a sign that it's a step ahead in Ph 3. Just read my comment properly. Thanks.
I think that the FDA appoints a DMC when its own staff doesn't have required expertise for evaluating results or its eavaluation is unlikely to be complete and needs outside help.
Where did you get this from? If it's authentic, it's really a good news and means that Scarlett and company does do something!!
Yes, DMC is an important arm of the licensing process. I am not sure if appointment of such a committee is really a sign of a step ahead in the process.
The SA writers are apparently paid basgers who must have been tied to WS machinery run by hedge funds and MMs. you ar foolish if you believe what they say in the end.
This is what the folks with some brain need to know and not get brainwashed by a chain of liers from SA and Motley Fools and, of course, the paid bashers on this board who, like vermin, have infested this board.
I think the MDS trial's potential success should help consideration of the continuation decision by Janssen, even if it's based simply on the MF trial. My presumptoion is that the continuation is forthcoming, sooner or later. It's in the interest of all parties - the patients, JNJ, Geron and also the FDA. I hope that the guys at Geron do not muddy the situation for shareholders with their acqusition bomb!!
This is scientifically different than in cancers where IMET is proven to be effective. It will be interesting to see if IMET is also useful in dealing with cardio disorders. If so, expansion of this compound's use will be much greater than even Janssen may have thought!
I wonder, if you really believe so, why are you still in GERN! Can't you find some more reliable and rewarding stocks even if you are a day trader? There must be hundreds of those in the market!!!